文献速递类风湿关节炎

类风湿关节炎循环破骨前体中PGC-1β/NFATc1通路激活与骨破坏相关

Activation of the Peroxisome Proliferator-Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2019-07-03

本研究探讨PGC-1β在类风湿关节炎循环破骨前体中的作用及其与骨破坏的关联。RA外周血CD14+单核细胞中PGC-1β表达增加,与影像学关节破坏正相关;敲低PGC-1β抑制破骨细胞分化和骨吸收,过表达则增强,且PGC-1β通过结合NFATc1启动子激活转录。结论提示PGC-1β/NFATc1通路激活与RA骨破坏相关,可能成为新治疗靶点。

要点

  • RA外周血CD14+单核细胞PGC-1β核积累增加,破骨生成能力强于健康对照。
  • PGC-1β蛋白表达与影像学关节破坏正相关(r=0.396-0.413,均P<0.05)。
  • PGC-1β通过结合NFATc1启动子激活转录,促进破骨细胞分化和骨吸收。

核心结论

  • RA循环破骨前体中PGC-1β/NFATc1通路激活与骨破坏相关,可能成为新治疗靶点。

研究设计与样本

  • 研究比较RA患者与健康对照外周血CD14+单核细胞,并通过慢病毒载体调控PGC-1β表达后体外培养成熟破骨细胞。

主要发现

  • RA外周血CD14+单核细胞PGC-1β核积累增加,破骨生成能力强于健康对照。
  • PGC-1β蛋白表达与影像学关节破坏正相关(r=0.396-0.413;均P<0.05)。
  • PGC-1β敲低使cathepsin K、TRAP、MMP-9表达降低51-82%,并抑制破骨分化和骨吸收活性。
  • PGC-1β过表达使上述标志物增加1.5-1.8倍并增强破骨生成。
  • NFATc1抑制剂VIVIT可抑制过表达PGC-1β的效应;ChIP和双荧光素酶报告基因显示PGC-1β结合NFATc1启动子并激活转录。

临床怎么用

  • 监测RA患者外周血CD14+单核细胞PGC-1β表达可能有助于评估骨破坏风险。
  • 靶向PGC-1β/NFATc1通路可能为RA骨破坏提供新的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Activation of osteoclastogenesis at the bone site in rheumatoid arthritis (RA) is well established. The mechanisms by which circulating osteoclast precursors contribute are still unclear. Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β) is implicated in transcriptional regulation of osteoclastogenesis in mouse models. This study was undertaken to investigate the contribution of PGC-1β to circulating osteoclast precursors and its link to bone destruction in RA. METHODS: PGC-1β expression in RA peripheral blood CD14+ monocytes was increased and showed correlation with joint destruction shown on radiographs. Cells from RA patients or healthy controls were transfected with a lentivirus vector for PGC-1β gene silencing or overexpression and cultured with macrophage colony-stimulating factor and RANKL. Bone resorption activity, bone-degrading enzymes, and signaling molecules were measured in these mature osteoclasts. RESULTS: Increased nuclear accumulation of PGC-1β was observed in RA peripheral blood CD14+ monocytes, and these cells had stronger osteoclastogenesis than in healthy controls. PGC-1β protein expression was positively correlated with radiographic joint destruction (r = 0.396-0.413; all P < 0.05). PGC-1β knockdown suppressed (51-82% reduction) the expression of cathepsin K, tartrate-resistant acid phosphatase (TRAP), and matrix metalloproteinase 9 (MMP-9), as well as osteoclast differentiation and bone resorption activity. Conversely, PGC-1β overexpression increased these markers (by 1.5-1.8-fold) and osteoclastogenesis. VIVIT, an inhibitor of NFATc1 activation, inhibited the effect of overexpressed PGC-1β by reducing cathepsin K, TRAP, and MMP-9 expression. Chromatin immunoprecipitation assay and dual-luciferase reporter gene assay showed PGC-1β bound to NFATc1 promoter, leading to transcriptional activation. CONCLUSION: Activation of the PGC-1β/NFATc1 pathway in circulating osteoclast precursors was associated with bone destruction in RA. This may represent a new treatment target.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ma JD, Jing J, Wang JW, et al. Activation of the Peroxisome Proliferator-Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis. Arthritis Rheumatol. 2019. PMID: 30802366. doi:10.1002/art.40868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。